GAAP EPS was $0.04 compared to a loss of $0.01 in the second quarter last year.

Non-GAAP EPS was $0.07 compared to $0.00 in the second quarter last year.

EBITDA increased 1,501.7% to $1.9 million, compared to $0.1 million last year.

"We are very pleased with our second quarter sales performance. We reported strong organic revenue growth of 13.4% year-over-year, and our total revenue growth exceeded 20% year-over-year including the partial-period contributions from our acquisition of Sterimedix Limited," said David M. Hable, the Company's President and Chief Executive Officer. "We continue to be encouraged by the progress we are making in the commercialization of the VersaVIT 2.0 system -- the largest organic growth driver of our ophthalmic business in the second quarter -- and our valuable relationships with our OEM customers continued to pay dividends this quarter as better-than-expected demand for our disposables and capital equipment drove strong sales growth compared to last year. Synergetics' performance over the first six-months of fiscal year 2015 has been very strong with sales up 13.7% year-over-year, operating profit up 132.1% and cash flow from operations of $4.8 million. We expect continued strength in our operating and financial results over the balance of fiscal 2015."

Second Quarter Results

Second quarter of fiscal 2015 sales totaled $18.2 million, an increase of 20.5%, compared to sales of $15.1 million in the second quarter of fiscal 2014. Total sales included contributions from our acquisition of Sterimedix Limited of $1.1 million, attributable to the period of December 10, 2014 to January 31, 2015. Second quarter sales performance was driven primarily by a 36.4% increase in Neurosurgery sales and an 8.9% increase in ophthalmic sales. Other sales increased 116.8% year-over-year.

Following the completion of the acquisition of Sterimedix, the Company assessed its sales presentation format and determined that a more comprehensive breakdown of its ophthalmic and neurosurgery sales is appropriate to more completely describe its revenues by market, as compared to reporting revenues by distribution category. The following table presents the Company's revised presentation of reporting enterprise-wide sales by market, as well as the previous presentation of reporting revenues by distribution category. The Company will provide sales results under both presentation formats for the balance of fiscal 2015 and will transition to the new presentation format of sales based upon market thereafter.

($'s in thousands)

Three Months Ended January 31, 2015

Three Months Ended January 31, 2014

% Change y/y

Six Months Ended January 31, 2015

Six Months Ended January 31, 2014

% Change y/y

Net Sales: Presentation based upon market

Ophthalmic (1)

$

9,985

$

9,165

8.9

%

$

19,510

$

18,129

7.6

%

Neurosurgery (2)

7,894

5,788

36.4

%

14,912

12,245

21.8

%

Other (3)

310

143

116.8

%

414

252

64.3

%

Total:

$

18,189

$

15,096

20.5

%

$

34,836

$

30,626

13.7

%

Net Sales: Presentation based upon distribution

Ophthalmic(4)

$

8,228

$

8,739

(5.8

%)

$

16,958

$

17,237

(1.6

%)

OEM (5)

9,784

6,123

59.8

%

17,470

12,971

34.7

%

Other (6)

177

234

(24.4

%)

408

418

(2.4

%)

Total:

$

18,189

$

15,096

20.5

%

$

34,836

$

30,626

13.7

%

Total ophthalmic sales increased 8.9% to $10.0 million, compared to $9.2 million in the second quarter of fiscal 2014. Domestic ophthalmic sales decreased 5.0% primarily due to declines in our base ophthalmic business offset, partially, by sales of VersaVIT™ and procedural kits. International ophthalmic sales increased 27.2% year-over-year primarily due to the addition of Sterimedix sales from December 10, 2014 through January 31, 2015, partially offset by a 4.3% decrease in international ophthalmology direct and distributor sales, primarily due to foreign currency adjustments.

Total neurosurgery sales increased 36.4% to $7.9 million, compared to $5.8 million in the second quarter of fiscal 2014. The increase in neurosurgery sales benefited primarily from strong volumes of disposable products and generators sold to Codman and Stryker compared to last year. Other sales increased 116.8% to $310,000, compared to $143,000 last year, primarily due to the addition of Sterimedix aesthetics sales from December 10, 2014 through January 31, 2015.

Total domestic sales increased 16.6% to $12.9 million in the second quarter of fiscal 2015, driven by higher neurosurgery sales, which are recorded as Domestic sales, partially offset by a 5.0% decline in domestic ophthalmic sales compared to last year. International sales increased 31.0% to $5.3 million primarily due to the addition of Sterimedix sales December 10, 2014 through January 31, 2015, partially offset by the 4.3% decrease in international ophthalmology sales related to the impacts of foreign currency exchange in the period.

Capital equipment sales increased 44.9% to $2.3 million, or 12.9% of sales in the second quarter of fiscal 2015 compared to $1.6 million, or 10.7% of sales, in the second quarter of fiscal 2014. Disposable product sales increased 18.0% to $15.5 million, or 85.4% of sales this year, compared to sales of $13.2 million, or 87.2% of sales in the second quarter of fiscal 2014.

Gross profit for the second quarter of fiscal 2015 totaled $9.6 million, or 52.7% of sales, compared to $8.4 million, or 55.6% of sales, in the second quarter of fiscal 2014. Year-over-year gross margin performance was driven by a product mix shift to neurosurgical sales from ophthalmic sales compared to last year, costs related to our final production at the King of Prussia facility, foreign currency exchange and inventory purchase price allocation related to our acquisition of Sterimedix.

Total operating expenses decreased 4.4% year-over-year to $8.4 million, or 46.1% of sales, in the second quarter of fiscal 2015 from $8.8 million, or 58.1% of sales, in the comparable 2014 period. Research and development expenses decreased 32.1% to $1.0 million, or 5.7% of sales, compared to 10.0% of sales last year. Sales and marketing expenses increased 0.4% to $3.6 million, or 20.0% of sales, compared to 24.0% of sales last year. General and administrative expenses decreased 2.0% to $2.9 million, or 16.2% of sales, compared to 19.9% of sales last year. Total operating expenses also increased due to higher expenses related to the Company's closure of its King of Prussia facility compared to the prior year period.

Reported operating income for the second quarter of fiscal 2015 increased $1.6 million to $1.2 million, or 6.6% of sales, compared to an operating loss of $0.4 million last year. Reported net income increased $1.2 million to approximately $1.0 million, or $0.04 per diluted share, compared to a loss of $0.2 million, or $0.01 per diluted share, for the same period of fiscal 2014.

As of January 31, 2015, the Company had approximately $8.9 million in cash and $2.75 million in interest-bearing debt. Cash flows provided by operating activities were $4.8 million for the six months ended January 31, 2015, compared to cash flows used by operating activities of $302,000 for the comparable fiscal 2014 period.

Conference Call Information

Synergetics USA, Inc. will host a conference call on Tuesday, March 10, 2015 at 4:00 p.m. Central Time (5:00 p.m. Eastern) to review the Company's results for the fiscal second quarter ended January 31, 2015. The toll free dial-in number to participate live on this call is (800) 588-4973, confirmation code 39067049. For callers outside the U.S., the number is (847) 230-5643. The conference call will also be available live via webcast at http://www.synergeticsusa.com. A replay will be available on the Company's website for approximately 30 days.

Notes to Accompany the Enterprise-wide Sales Table:

(1) Net sales from ophthalmic represent all sales of ophthalmic devices from direct sales representatives, distribution partners and OEMs. Recognition of deferred revenue of $322,000 and $644,000 from Alcon, Inc. is included in this category for the three and six months ended January 31, 2015 and 2014, respectively.

(2) Net sales from neurosurgery represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and certain neurosurgery disposables sold through distribution. Many of the products that the Company sells to its neurosurgery OEM customers are shipped to their non-U.S. customers in various countries around the world, but are included in the Company's domestic revenues.

(3) Other net sales represent all sales of aesthetic devices, freight and other miscellaneous revenues.

(5) Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products. Recognition of deferred revenues of $322,000 and $644,000 from Alcon, Inc. is included in this category for the three and six months ended January 31, 2015 and 2014, respectively. Many of the products that the Company sells to its neurosurgery OEM customers are shipped to their non-U.S. customers in various countries around the world, but are included in the Company's domestic revenues.

Through continuous improvement and development of our people, our mission is to design, manufacture and market innovative surgical devices, capital equipment, accessories and disposables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients.

Synergetics USA, Inc. (the "Company") is a leading supplier of precision surgical devices. The Company's primary focus is on the disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent sales distributor organizations, both domestically and internationally, and important strategic alliances with market leaders. The Company's product lines focus on precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company's website address is http://www.synergeticsusa.com.

Use of Non-GAAP Financial Information

The Company measures its performance primarily through its growth in revenue and operating profit. In addition to results reported in accordance with GAAP, the Company provides adjusted operating income and margin, EBITDA and adjusted diluted earnings per share. These adjusted amounts consist of GAAP amounts excluding the adjustment for exit costs occurring during the period. Adjusted earnings per diluted share were calculated by dividing adjusted net income for diluted earnings per share by diluted weighted average shares outstanding. The Company believes that the presentation of adjusted operating income and margin, EBITDA and adjusted diluted earnings per share provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

These non-GAAP measures are considered by the Company's Board of Directors and management as a basis for measuring and evaluating the Company's overall operating performance and ability to service debt. They are presented to enhance an understanding of the Company's operating results and are not intended to represent cash flow or results of operations.

These non-GAAP measures are not in accordance with, or an alternative to, measures prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

Forward-Looking Statements

Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the year ended July 31, 2014 as updated from time to time in our filings with the Securities and Exchange Commission. The Company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

Synergetics USA, Inc. and Subsidiaries

Condensed Consolidated Statements of Income and Comprehensive (Loss) Income (Unaudited)

Three and Six Months Ended January 31, 2015 and 2014

(Dollars in thousands, except share and per share data)

Three Months Ended January 31, 2015

Three Months Ended January 31, 2014

Six Months Ended January 31, 2015

Six Months Ended January 31, 2014

Net sales

$

18,189

$

15,096

$

34,836

$

30,626

Cost of sales

8,605

6,698

15,982

13,304

Gross profit

9,584

8,398

18,854

17,322

Operating expenses

Research and development

1,028

1,513

2,227

2,710

Sales and marketing

3,643

3,630

7,339

7,205

Medical device excise tax

116

115

244

240

Exit costs

657

514

719

514

General and administrative

2,942

3,003

5,970

5,638

8,386

8,775

16,499

16,307

Operating income (loss)

1,198

(377

)

2,355

1,015

Other income (expense)

Investment income

1

3

2

6

Interest expense

(14

)

--

(14

)

--

(13

)

3

(12

)

6

Income (loss) from operations before provision (benefit) for income taxes